...
首页> 外文期刊>Biological & pharmaceutical bulletin >TJN-259 Improves Mesangial Lesions in Experimental Immunoglobulin A Nephropathy in ddY Mice
【24h】

TJN-259 Improves Mesangial Lesions in Experimental Immunoglobulin A Nephropathy in ddY Mice

机译:TJN-259可改善ddY小鼠实验性免疫球蛋白A肾病的系膜病变

获取原文
获取原文并翻译 | 示例
           

摘要

TJN-259 is a chemical substance based on the structural features of the botanically derived ingredient acteoside. This study was performed in order to elucidate the antinephritic effects of TJN-259 in experimental immunoglobulin A (IgA) nephropathy. In this study, 28-week-old ddY mice were used as a spontaneous model of IgA nephropathy. With regard to spontaneous IgA nephropathy, we investigated the effects of TJN-259 administered from 28 to 40 weeks. In addition, an accelerated model of IgA nephropathy was experimentally induced in ddY mice by oral administration of bovine serum albumin, followed by reticuloendothelial blocking by colloidal carbon injection and heminephrectomy. At 10 weeks after the 3rd carbon injection, we also examined the effects of TJN-259 on accelerated IgA nephropathy. To investigate the effects of TJN-259 on transforming growth factor (TGF)-beta 1 production in accelerated IgA nephropathy, kidneys were isolated and measured TGF-beta 1 by the enzyme-linked immunosorbent assay (ELISA) method. The administration of TJN-259 to mice with spontaneous IgA nephropathy decreased the incidence of mesangial expansion as well as the number of nuclei per glomerular cross-section in comparison with that of non-treated mice. In addition, TJN-259 treatment prevented the increase in the incidence of mesangial expansion, crescent formation, and segmental sclerosis in glomeruli in accelerated IgA nephropathy. TJN-259 also inhibited the increased immunostaining score of collagen type IV and TGF-beta 1 in glomeruli of accelerated IgA nephropathy. Treatment with TJN-259 inhibited the increases in renal total and mature TGF-beta 1 protein levels in accelerated type IgA nephropathy. TJN-259 failed to inhibit the increase in serum IgA levels in both models. These results suggest that TJN-259 was an effective treatment against IgA nephropathy in ddY mice, acting via the suppression of TGF-beta 1 production in glomeruli.
机译:TJN-259是一种化学物质,其基于植物来源成分岩藻皂甙的结构特征。进行这项研究是为了阐明TJN-259在实验性免疫球蛋白A(IgA)肾病中的抗肾炎作用。在这项研究中,将28周龄的ddY小鼠用作IgA肾病的自发模型。关于自发性IgA肾病,我们研究了在28到40周内服用TJN-259的效果。此外,通过口服牛血清白蛋白,然后通过胶体碳注射和肾肾切除术阻断网状内皮,实验性地在ddY小鼠中诱导了IgA肾病加速模型。在第3次注碳后第10周,我们还检查了TJN-259对加速IgA肾病的影响。为了研究TJN-259对加速的IgA肾病中转化生长因子(TGF)-β1产生的影响,分离肾脏并通过酶联免疫吸附测定(ELISA)方法测量TGF-β1。与未经治疗的小鼠相比,对患有自发性IgA肾病的小鼠给予TJN-259可以降低肾小球系膜扩张的发生率以及每个肾小球横截面的核数。此外,TJN-259治疗可防止IgA加速肾病中肾小球系膜扩张,新月形形成和节段性硬化的发生率增加。 TJN-259还抑制了加速的IgA肾病肾小球中IV型胶原和TGF-β1的免疫染色评分。 TJN-259的治疗抑制了IgA型加速性肾病中肾脏总TGF-β1和成熟TGF-β1蛋白水平的增加。在两种模型中,TJN-259均无法抑制血清IgA水平的增加。这些结果表明,TJN-259是通过抑制肾小球中TGF-β1的产生而有效治疗ddY小鼠的IgA肾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号